Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;326:1158-1159 (31 May), doi:10.1136/bmj.326.7400.1158
Hib exemplifies need for continued surveillance after changes in vaccines
| The first 150 words of the full text of this article appear below. |
The chief medical officer has recently recommended that all children in the United Kingdom aged 6 months to 4 years should receive a single dose of Haemophilus influenzae type b vaccine. This is in response to a rise in the incidence of Hib disease over the past four years. The reasons for the increase are complex, but evidence points strongly to an effect of a temporary change to the use of a Hib vaccine combined with diphtheria, tetanus, and acellular pertussis (DTaP).
Before the Hib conjugate vaccine was introduced in 1992, Hib was the most
common cause of bacterial meningitis in children. Rapid control of Hib disease
was achieved by combining routine infant immunisation at 2, 3, and 4 months of
age with a catch-up programme for children aged up to 4 years. Initially Hib
vaccine was given as a separate injection, but in 1996 a combined DTP-Hib
vaccine was
Paul T Heath, consultant in paediatric infectious diseases
Vaccine Institute and Department of Child Health, St George's Hospital Medical School, London SW170RE (pheath@sghms.ac.uk)
Mary E Ramsay, consultant epidemiologist
Immunisation Division, Health Protection Agency Communicable Disease Surveillance Centre, London NW9 5EQ
Read all Rapid Responses